Medicine
Takhzyro 150 mg/1 mL injection
Takhzyro 150 mg/1 mL injection is a prescription medicine containing Lanadelumab for subcutaneous use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C). Do not…
Key facts
- Active ingredient (INN)
- Lanadelumab
- Brand
- Takhzyro
- Strength
- 150 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1 mL
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze. Do not shake. Keep the prefilled syringe in the original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B06AC05 Lanadelumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 February 2023
- Identifiers
- RxCUI 2055645, 2055650, 2593416 +3DailyMed set ID 15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8NDC 47783-645Application BLA761090
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 47783-645-01 | Takeda Pharmaceuticals | 3 February 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lanadelumab
Clinical summary
Lanadelumab is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. It is available as injection for subcutaneous use. MedsAcross supplies Lanadelumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LanadelumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TAKHZYRO prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Takhzyro: European public assessment report (EPAR) · European Medicines Agency
Need Takhzyro 150 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.